Product Reports Resources Pricing Login Book a demo

eMed

Health Tech & Medtech · Miami, United States · Founded 2020

eMed is a digital healthcare company dedicated to managing population health through scalable, AI-driven solutions. Founded in 2020 initially to democratize access to diagnostics like at-home infectious disease tests, the company has since pivoted its core mission to become a definitive platform for employer-sponsored GLP-1 and weight management programs. By leveraging its proprietary Empathetic AI platform, eMed combines remote diagnostics with clinician-led prescriptions and continuous adherence coaching to deliver superior health outcomes for patients dealing with obesity and related comorbidities. The company primarily serves employers and government payers, operating within the business-to-business sector. By adopting a subscription-based, capitated financial model, eMed directly addresses the escalating corporate healthcare costs associated with popular GLP-1 weight-loss medications. This approach shifts financial risk and helps employers provide highly requested health benefits while simultaneously capping runaway healthcare expenditures. Revenue is generated through these structured enterprise contracts and population health management services. eMed's platform stands out by bridging the gap between medication access and patient compliance, boasting member adherence rates that significantly exceed industry norms. Key features include end-to-end clinical oversight, biomarker tracking, and an agentic AI system that actively engages patients to ensure they stay on their treatment paths. The company's structured clinical support strategy effectively tackles chronic conditions like obesity and type 2 diabetes, providing measurable health improvements and a high return on investment for enterprise clients. Keywords: digital health, telehealth, population health, GLP-1 management, employer benefits, artificial intelligence, weight management, chronic care, remote diagnostics, value-based care

Investors

9 investors on eMed's cap table

Sourced from Dealroom's funding history.

Series A 8 investors entered at this stage
Joe Lonsdale
Jeff Aronin
Tom Brady
Ara Cohen
Antonio Gracias
Linda Yaccarino
Tom Ricketts
RJ Melman
Series B+ 1 investor entered at this stage
Aon

Global footprint

Where eMed has talent and traffic

Workforce by country
🇺🇸 United States · Miami HQ
Book a demo for the full country breakdown
Web traffic by country
130K monthly visits
across markets
🇺🇸 United States81.8%
🇬🇧 United Kingdom7.9%
🇨🇦 Canada5.9%
🇮🇳 India1.5%
🇩🇰 Denmark0.9%
Top 5 markets shown

Talent graph

The shape of eMed's talent

Dealroom maps eMed's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

187 team members profilednamed & role-tagged by Dealroom
288 employeestotal headcount
5 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock eMed's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about eMed

An AI-synthesized read of the highest-engagement posts about eMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See eMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.